Biobank for Inflammatory Chronic Diseases and Osteoporosis of TOULouse
Overview
- Phase
- Not Applicable
- Intervention
- Blood sampling
- Conditions
- Rheumatoid Arthritis
- Sponsor
- University Hospital, Toulouse
- Enrollment
- 2000
- Locations
- 1
- Primary Endpoint
- EULAR response after 3 months
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.
Detailed Description
Biologic ant targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) have greatly improved the prognosis of chronic inflammatory diseases. To date, many bDMARDs and tsDMARDs targeting different immunologic mechanisms are available to treat RA, SpA or PsA. However, the choice of the treatment and its mechanism of action is based on physician decision and experience. Indeed, predictive clinical and biological factors associated with therapeutic response that could help the physician to make his/her choice are lacking. The aim of BIOTOUL is to collect and store biologic samples in patients with RA, SpA or PsA who begin a new bDMARD or tsDMARD. This biobank will permit to study several biomarkers and assess the association between such markers and response to therapy. Furthermore, osteoporosis is a chronic disease leading to fractures and disability. Several ant-osteoporotic drugs are now available and biomarker(s) that would help the physician to choose the best therapeutic sequence are lacking. BIOTOUL will also include patients with osteoporosis to identify biomarkers associated with severity and response to anti-osteoporotic treatments.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Chronic inflammatory rheumatism including RA, SpA or PsA or patients with primary or secondary osteoporosis
- •With National Health Assurance
- •Able to consent to the study
Exclusion Criteria
- •Pregnancy or breastfeeding
- •Not able to give a consent
- •Severe anemia (Hb\<10g/L)
Arms & Interventions
patients initiating a biotherapy or a target treatment
Blood sampling
Intervention: Blood sampling
patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology
Blood sampling
Intervention: Blood sampling
Outcomes
Primary Outcomes
EULAR response after 3 months
Time Frame: after 3 months
EULAR response after 3 months